Learn More
PURPOSE To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM). PATIENTS AND METHODS Symptomatic WM patients, untreated or previously treated,(More)
PURPOSE For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less(More)
7543 Background: WM is a B cell lymphoma characterized by a serum monoclonal IgM and marrow infiltration by lymphoplasmacytoid cells. Bortezomib is a proteasome inhibitor active in myeloma and other(More)